BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 37685923)

  • 1. KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control.
    Le Calvez-Kelm F; Foll M; Wozniak MB; Delhomme TM; Durand G; Chopard P; Pertesi M; Fabianova E; Adamcakova Z; Holcatova I; Foretova L; Janout V; Vallee MP; Rinaldi S; Brennan P; McKay JD; Byrnes GB; Scelo G
    Oncotarget; 2016 Nov; 7(48):78827-78840. PubMed ID: 27705932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of
    Fujii T; Barzi A; Sartore-Bianchi A; Cassingena A; Siravegna G; Karp DD; Piha-Paul SA; Subbiah V; Tsimberidou AM; Huang HJ; Veronese S; Di Nicolantonio F; Pingle S; Vibat CRT; Hancock S; Berz D; Melnikova VO; Erlander MG; Luthra R; Kopetz ES; Meric-Bernstam F; Siena S; Lenz HJ; Bardelli A; Janku F
    Clin Cancer Res; 2017 Jul; 23(14):3657-3666. PubMed ID: 28096270
    [No Abstract]   [Full Text] [Related]  

  • 3. [Mutation of the K-ras oncogene in pancreatic carcinoma, and application of its detection in pancreatic juice to diagnose pancreatic carcinoma].
    Sawabu N; Watanabe H; Yamaguchi Y; Okai T
    Nihon Rinsho; 1995 Feb; 53(2):511-7. PubMed ID: 7699881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms.
    Cowzer D; Shah RH; Chou JF; Kundra R; Punn S; Fiedler L; DeMore A; Capanu M; Berger MF; Reidy-Lagunes D; Raj N
    Endocr Relat Cancer; 2024 Apr; 31(4):. PubMed ID: 38252063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective epigenetic alterations in RNF43 in pancreatic exocrine cells from high-fat-diet-induced obese mice; implications for pancreatic cancer.
    Araki T; Miwa N
    BMC Res Notes; 2024 Apr; 17(1):106. PubMed ID: 38622664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-Free Tumor DNA Detection-Based Liquid Biopsy of Plasma and Bile in Patients with Various Pancreatic Neoplasms.
    Jain M; Atayan D; Rakhmatullin T; Dakhtler T; Popov P; Kim P; Viborniy M; Gontareva I; Samokhodskaya L; Egorov V
    Biomedicines; 2024 Jan; 12(1):. PubMed ID: 38255325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer.
    Stefanoudakis D; Frountzas M; Schizas D; Michalopoulos NV; Drakaki A; Toutouzas KG
    Curr Issues Mol Biol; 2024 Mar; 46(4):2827-2844. PubMed ID: 38666907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correction to: Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer.
    Cancer Sci; 2024 May; ():. PubMed ID: 38812359
    [No Abstract]   [Full Text] [Related]  

  • 9. Lugtenburg PJ, Mutsaers PGNJ. How I treat older patients with DLBCL in the frontline setting. Blood. 2023;141(21):2566-2575.
    Blood; 2023 Sep; 142(12):1103. PubMed ID: 37733375
    [No Abstract]   [Full Text] [Related]  

  • 10. Prognostic role of cell-free DNA biomarkers in pancreatic adenocarcinoma: A systematic review and meta-analysis.
    Bunduc S; Gede N; Váncsa S; Lillik V; Kiss S; Dembrovszky F; Eróss B; Szakács Z; Gheorghe C; Mikó A; Hegyi P
    Crit Rev Oncol Hematol; 2022 Jan; 169():103548. PubMed ID: 34843928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of circulating cell-free DNA in patients with pancreatic cancer: A systemic review and meta-analysis.
    Chen L; Zhang Y; Cheng Y; Zhang D; Zhu S; Ma X
    Gene; 2018 Dec; 679():328-334. PubMed ID: 30227250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutation Analysis of Pancreatic Juice and Plasma for the Detection of Pancreatic Cancer.
    Levink IJM; Jansen MPHM; Azmani Z; van IJcken W; van Marion R; Peppelenbosch MP; Cahen DL; Fuhler GM; Bruno MJ
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Digital PCR-based plasma cell-free DNA mutation analysis for early-stage pancreatic tumor diagnosis and surveillance.
    Okada T; Mizukami Y; Ono Y; Sato H; Hayashi A; Kawabata H; Koizumi K; Masuda S; Teshima S; Takahashi K; Katanuma A; Omori Y; Iwano H; Yamada M; Yokochi T; Asahara S; Kawakubo K; Kuwatani M; Sakamoto N; Enomoto K; Goto T; Sasajima J; Fujiya M; Ueda J; Matsumoto S; Taniue K; Sugitani A; Karasaki H; Okumura T
    J Gastroenterol; 2020 Dec; 55(12):1183-1193. PubMed ID: 32939577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An 8q24 Gain in Pancreatic Juice Is a Candidate Biomarker for the Detection of Pancreatic Cancer.
    Levink IJM; Srebniak MI; De Valk WG; van Veghel-Plandsoen MM; Wagner A; Cahen DL; Fuhler GM; Bruno MJ
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Digital next-generation sequencing identifies low-abundance mutations in pancreatic juice samples collected from the duodenum of patients with pancreatic cancer and intraductal papillary mucinous neoplasms.
    Yu J; Sadakari Y; Shindo K; Suenaga M; Brant A; Almario JAN; Borges M; Barkley T; Fesharakizadeh S; Ford M; Hruban RH; Shin EJ; Lennon AM; Canto MI; Goggins M
    Gut; 2017 Sep; 66(9):1677-1687. PubMed ID: 27432539
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.